Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

PEPIDH1M vaccine

Phase 1Vaccine

KKaty Peters, MD, PhD

1

Indications

2

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Grade Glioma of BrainRecruiting

Low Grade Glioma of BrainPhase 1

Recruiting

Timeline

Expected Milestones

Q3 2029

Phase 1Recruiting

Low Grade Glioma of Brain

NCT05609994

Clinical

Trials by Indication[1]

Glioma1 trial

IDH1 Peptide Vaccine for Recurrent Grade II Glioma

Completed·KKaty Peters, MD, PhD·Phase 1·NCT02193347·24 enrolled

Low Grade Glioma of Brain1 trial

ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Recruiting·KKaty Peters, MD, PhD·Phase 1·NCT05609994·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for PEPIDH1M vaccine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEPIDH1M vaccine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEPIDH1M vaccine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Katy Peters, MD, PhD company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 1[1]
Company: KKaty Peters, MD, PhD

Related News